Program Overview
Georgia’s medical-cannabis program began with the Haleigh’s Hope Act (HB 1, 2015) — the first medical-cannabis statute in the Bible Belt, named for 4-year-old Haleigh Cox — and was finally given an in-state production framework by Georgia’s Hope Act (HB 324, 2019). First legal sale happened April 28, 2023, eight years and 12 days after HB 1. The program is administered by the Department of Public Health (DPH) for patient registration and the Georgia Access to Medical Cannabis Commission (GMCC) for production and dispensing.
The program is the most restrictive in any state that is currently dispensing product: a 5% THC cap (the lowest in the U.S.), no smokable flower, no vape cartridges, no conventional edibles, and product limited to oils, tinctures, capsules, lozenges, topicals, and transdermal patches. About 34,500 patients are registered (~0.3% of Georgia’s population, the lowest patient-density rate in the country).
Georgia is also the first U.S. state to authorize independent-pharmacy dispensing of medical cannabis (rollout October 2024; ~120 pharmacies signed on; CVS and Walgreens declined; DEA warning letters Nov 2024). See pharmacy dispensing.
The Georgia Department of Public Health administers the Low THC Oil Patient Registry under O.C.G.A. § 16-12-191. The Georgia Access to Medical Cannabis Commission regulates production and dispensing.
Georgia DPH Low THC Oil Patient Registry
The Four Topics, Four Dedicated Pages
The medical-card section is split into four pages so you can go straight to what you need:
Pending Expansion: SB 220 (2026)
Sen. Matt Brass and Rep. Mark Newton MD’s Putting Georgia’s Patients First Act awaits Gov. Kemp’s signature decision (~May 12, 2026). If signed it would replace “low THC oil” with “medical cannabis,” remove the 5% THC cap, authorize vaporization for patients 21+, and expand the qualifying-conditions list (lupus, severe arthritis, severe insomnia added; “severe or end-stage” qualifier removed for cancer, ALS, MS, Parkinson’s, sickle cell, Alzheimer’s, peripheral neuropathy). See the SB 220 watch page.
Program Scale
| Metric | Value (May 2026) |
|---|---|
| Active Low-THC Oil patient cards | ~34,500 registered (per Botanical Sciences CEO Gary Long, March 2026 testimony; ~33,700 + 2,300 caregivers in late 2025 GMCC reporting) |
| Adoption rate (% of state pop., ~11.3M) | ~0.3% — lowest of any U.S. medical-cannabis program |
| Active dispensaries | ~18 + ~120 partner pharmacies |
| In-state production licenses | 2 Class 1 + 4 Class 2 (cap fully issued) |
| Patient registry fee | $30 + $3.75 secure-payment service fee |
| Card validity | 5 years (extended from 2 in Oct 2024) |
| Possession limit | 20 fluid ounces of low-THC oil |
| THC potency cap | 5% by weight (CBD ≥ THC); SB 220 (2026) would remove if signed |
| First in-state legal sale | April 28, 2023 — 8 years 12 days after Haleigh’s Hope was signed |
| Most-cited qualifying conditions | Intractable pain + PTSD (75%+ combined) |
| Top participating physicians | ~700 statewide |
Sources: Georgia Access to Medical Cannabis Commission (GMCC); Department of Public Health Low-THC Oil Registry; Botanical Sciences industry testimony; AJC reporting.
Historical Context
Georgia’s program is the product of a decade-long compromise between conservative legislators, law-enforcement opposition, social-conservative caucuses, and a small coalition of parents (Janea Cox, Suzeanna Brill) who pressed for legal access for their seriously ill children. The full story is told in:
- Haleigh’s Hope Act (HB 1, 2015) — the foundational statute
- Georgia’s Hope Act (HB 324, 2019) — the 9-year wait, GMCC, license litigation
- Practitioner certification — the bona fide doctor-patient relationship rule
- Pharmacy dispensing — first-in-the-nation rollout
Contact DPH
- Phone: (404) 463-1240
- Email: LowTHCOil@dph.ga.gov
- Registry page: dph.georgia.gov/low-thc-oil-patient-registry
- GMCC website: gmcc.georgia.gov
For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org